Literature DB >> 21466907

Characterization of Elastofibroma Dorsi with (18)FDG PET/CT: a retrospective study.

Y Blumenkrantz1, G L Bruno, C J González, M Namías, A R Osorio, P Parma.   

Abstract

UNLABELLED: Elastofibroma dorsi has been described in the literature as an unusual tumor or pseudotumor. However, autopsies and imaging studies have revealed that it is a non-negligible finding.
PURPOSE: The aim of this study has been to illustrate and become familiar with this type of lesion in order to prevent misdiagnosis.
MATERIALS AND METHODS: From 3 December 2008 to 5 January 2010, 1,751 patients were evaluated with (18)FDG-PET/CT. Of these, 29 cases of elastofibroma dorsi were recorded as an incidental finding. A retrospective and descriptive analysis was performed on this study series.
RESULTS: The study showed a prevalence of 1.66%. Out of the 29 findings, 22 (75.86%) were females and 7 (24.14%) males. Seventeen (58.62%) cases were bilateral, 12 (41.38%) unilateral and the SUVmax ranged from 1.4 to 3.2. These lesions were reported as soft tissue density images with mild or moderate diffuse metabolic activity.
CONCLUSION: The elastofibroma dorsi is a relatively common finding in PET/CT that should be known in order to avoid making wrong diagnoses.
Copyright © 2011 Elsevier España, S.L. and SEMNIM. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466907     DOI: 10.1016/j.remn.2011.01.006

Source DB:  PubMed          Journal:  Rev Esp Med Nucl        ISSN: 0212-6982


  9 in total

1.  Elastofibroma dorsi: Surgical indications and complications of a rare soft tissue tumor.

Authors:  Satoshi Nagano; Masahiro Yokouchi; Takashi Setoyama; Hiromi Sasaki; Hirofumi Shimada; Ichiro Kawamura; Yasuhiro Ishidou; Takao Setoguchi; Setsuro Komiya
Journal:  Mol Clin Oncol       Date:  2014-02-11

Review 2.  [Dorsal elastofibroma: retrospective study of 21 cases and review of literature].

Authors:  Azzouz Haddan; Fouad Zouaidia; Siham Masmoudi; Abdelmonim Moumni; Mohammed Mouanis; Ahmed Jahid; Zakia Bernoussi; Najat Mahassini
Journal:  Pan Afr Med J       Date:  2013-10-14

3.  Bilateral elastofibroma dorsi: a case report of an uncommon and under-diagnosed tumor.

Authors:  Stefanie Braun; Matthias Richter; Tom Ernst; Andreas Flade; Dirk Uhlmann
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-12-30

4.  Elastofibroma dorsi: Clinical evaluation of 61 cases and review of the literature.

Authors:  Mehmet Ali Deveci; Hilmi Serdar Özbarlas; Kıvılcım Eren Erdoğan; Ömer Sunkar Biçer; Mustafa Tekin; Cenk Özkan
Journal:  Acta Orthop Traumatol Turc       Date:  2016-10-22       Impact factor: 1.511

Review 5.  Elastofibroma Dorsi, a Rare Condition, with Challenging Diagnosis. Case Report and Literature Review.

Authors:  Octavian Neagoe; Cosmin Ioan Faur; Mihaela Ionică; Flavia Baderca; Roxana Folescu; Daniela Gurgus; Carmen Lăcrămioara Zamfir; Andrei Motoc; Mirela Loredana Grigoraș; Octavian Mazilu
Journal:  Medicina (Kaunas)       Date:  2021-04-12       Impact factor: 2.430

6.  Subscapular elastofibrolipoma treated with marginal resection: two case reports.

Authors:  Parviz Mardani; Hooman Kamran; Nazanin Ayare; Reza Shahriarirad; Pardis Shahabinejad; Bita Geramizadeh; Masoud Vafabin
Journal:  J Med Case Rep       Date:  2022-08-02

7.  Does elastofibroma dorsi occur more frequently on the same side with the dominant hand?

Authors:  Serda Kanbur Metin; Serdar Evman
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2022-04-27       Impact factor: 0.704

8.  Painful elastofibroma dorsi: a report of a case and a brief review of the literature.

Authors:  Evangelos Falidas; Dimitrios Arvanitis; Georgios Anyfantakis; Angelos Pazidis; Zacharoula Koukouli; Dimosthenis Miltiadou; Anastasia Koronaiou
Journal:  Case Rep Orthop       Date:  2013-01-14

9.  Unusual Presentation of Elastofibroma Dorsi on 18F-FDG-PET/CT: A Case Report.

Authors:  Steve P Martin; Joanna Gariani; Claire Tabouret Viaud
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.